{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:46Z","timestamp":1790314246907,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective nature of determining MM can result in ambiguity regarding this category in clinical practice and clinical trials. This study analyzed severity metrics in a large number of MG patients to propose criteria for MM-or-better. We utilized data obtained from 3800 MG patients who participated in nationwide cross-sectional surveys in Japan. Among these, 2784 patients with generalized MG were divided into two groups based on MG Foundation of America postintervention status: MM-or-better status (n = 1432); and improved-or-worse (I-or-worse) status (n = 1352). We compared severity metrics (MG-activities of daily living scale [MG-ADL], quantitative MG score [QMG], and MG composite scale [MGC]) between groups and calculated cutoff values to separate the two groups. Using these cutoffs, patients subjectively assigned as MM-or-better were classified into strict MM-or-better (below a cutoff) or optimistic MM-or-better (above a cutoff) groups, and clinical characteristics were then compared. Cutoff values for strict MM-or-better were MG-ADL \u22642, QMG \u22647, and MGC \u22644 (sensitivity 82.0%, 88.7%, and 87.4%; specificity 85.0%, 70.0%, and 77.9%; and accuracy 91.2%, 88.7%, and 90.7%, respectively). Mean values of the revised 15-item MG quality of life scale were significantly lower in the strict MM-or-better group than in the optimistic MM-or-better group. Quantitative criteria for MM-or-better appear likely to be useful in the context of rigorous clinical trials and also as reference information in clinical settings.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1502721","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:43:20Z","timestamp":1734936200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis"],"prefix":"10.3389","volume":"15","author":[{"given":"Genya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Nagane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Amino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Samukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori P.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.3.351","article-title":"Autoimmune myasthenia gravis","volume":"9","author":"Gilhus","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111.\/cen3.12731","article-title":"Japan MG registry: Chronological surveys over 10 years","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality of life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicenter cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalized myasthenia gravis (RAISE): a randomized, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomized, double-blind, placebo-controlled, multicenter study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalized myasthenia gravis (MycarinG): a randomized, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicenter, randomized, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","article-title":"Social disadvantages associated with myasthenia gravis and its treatment: a multicenter cross-sectional study","volume":"7","author":"Nagane","year":"2017","journal-title":"BMJ Open"},{"key":"B16","first-page":"140","volume-title":"Japanese Clinical Guidelines for Myasthenia Gravis 2014","year":"2014"},{"key":"B17","first-page":"193","volume-title":"Japanese Clinical Guidelines for Myasthenia Gravis\/Lambert\u2013Eaton Myasthenic Syndrome 2022","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for the management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for the management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis-specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cen3.12091","article-title":"Clinical features and treatment status of adult myasthenia gravis in Japan","volume":"5","author":"Murai","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies\u2013a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin Chim Acta"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"[amp]]lsquo;Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3083-6","article-title":"Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients","volume":"38","author":"Raggi","year":"2017","journal-title":"Neurol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082189","article-title":"Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales","volume":"11","author":"Diez-Porras","year":"2022","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.538","article-title":"Fatigue in myasthenia gravis: risk factors and impact on quality of life","volume":"6","author":"Hoffmann","year":"2016","journal-title":"Brain Behav"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11925-6","article-title":"Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study","volume":"270","author":"Chanson","year":"2023","journal-title":"J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1502721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:43:24Z","timestamp":1734936204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1502721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2024.1502721"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1502721","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"article-number":"1502721"}}